Clinical trials · Raleigh–Durham, NC
Metastatic Breast Cancer clinical trials in Raleigh–Durham
We’re tracking 64 recruiting metastatic breast cancer studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Morrisville, North CarolinaAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Cary, North CarolinaAges 18 years+ - NCT06216301RecruitingPhase 3
Electric fields with immunotherapy and chemo for advanced lung cancer
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Cary, North CarolinaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Cary, North CarolinaAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Cary, North CarolinaAges 18 years+ - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Cary, North CarolinaAges 18–55 - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Cary, North CarolinaAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Cary, North CarolinaAges 18–60 - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Cary, North CarolinaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Raleigh, North CarolinaAges Any age - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Raleigh, North CarolinaAges 18 years+ - NCT03769415Recruiting
Using tumor gene data to improve treatment in metastatic breast cancer
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
Raleigh, North CarolinaAges 18–99 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Raleigh, North CarolinaAges 18–130 - NCT05863195RecruitingPhase 3
Testing a liver pump with standard chemo for colorectal cancer that spread to the liver
This trial tests whether adding a special chemotherapy pump implanted in your liver (hepatic arterial infusion) to standard chemotherapy works better than standard chemotherapy alone for people whose colorectal cancer has spread only to the liver and cannot be removed by surgery. The pump delivers high doses of chemo directly to the liver to shrink tumors and possibly control the disease longer.
Raleigh, North CarolinaAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Durham, North CarolinaAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Durham, North CarolinaAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Durham, North CarolinaAges 18 years+ - NCT07194044RecruitingPhase 1
Testing a treatment schedule for metastatic Ewing sarcoma
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
Durham, North CarolinaAges 1 year+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Durham, North CarolinaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Durham, North CarolinaAges 18 years+ - NCT06795529Recruiting
Palliative care support for metastatic breast cancer
This study tests a palliative care program designed to improve quality of life for people with metastatic breast cancer. It may help you better manage symptoms and coordinate care with your oncology team.
Durham, North CarolinaAges 18 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Durham, North CarolinaAges 18 years+ - NCT05846789RecruitingPhase 2
Tocilizumab plus chemo for metastatic breast cancer
This trial tests whether adding tocilizumab, a drug that calms the immune system, to standard chemotherapy helps control certain advanced breast cancers. It is for people with triple-negative or ER-positive, HER2-negative breast cancer that has spread or come back.
Durham, North CarolinaAges 18 years+
Hear when a new Metastatic Breast Cancer trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Metastatic Breast Cancer trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting metastatic breast cancer studies listed above.
- Duke University Medical Center · 17 studies
- UNC Lineberger Comprehensive Cancer Center · 6 studies
- Duke Women's Cancer Care Raleigh · 5 studies
- Duke Cancer Center Cary · 4 studies
- Cone Health Cancer Center at Alamance Regional · 3 studies
- UNC Health Cancer Care Cary · 3 studies
- UNC Health Cancer Care Garner · 3 studies
- UNC Health Cancer Care Raleigh · 3 studies
What taking part in a metastatic breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic breast cancer studies in North Carolina.
Common questions
- Are there metastatic breast cancer clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 64 recruiting metastatic breast cancer studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic breast cancer study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic breast cancer studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.